In 1995, Lundbeck opened its Canadian subsidiary in Montreal, Quebec. For the first few years in Canada, two products were available for the treatment of schizophrenia. In 1999, a selective serotonin reuptake inhibitor (SSRI) became available for Canadian patients. In 2005, we introduced two more products: one for depression, anxiety and obsessive compulsive disorder, and another for moderate to severe Alzheimer’s disease.
In 2012, we launched a product for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar 1 disorder. In the last five years, we have introduced three innovative treatments for Canadians including a long acting injectable indicated for Schizophrenia and Bipolar I Disorder, an oral anti-depressant and an oral anti-psychotic indicated for Schizophrenia and adjunct treatment of Major Depressive Disorder.
As we continue to evolve, we will strive to help the people who are at the core of everything we do - patients - with the hope of making a positive impact on their lives.